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ABSTRACT _
The current level of noncompliance with prescription
medications exerts a tremendous burden on the health-
care system in terms of both cost and poor health. The
process of developing a program to improve compliance
for lipid therapy is twofold. First, patients must be met at
their specific level of need. This involves enabling, rein-
forcing, prompting, and problem solving. Second, the de-
livery of treatment must be addressed. Large centers and
I n the words of C. Everett Koop, "Drugs won'twork if people don't take them." Compliance
and persistence with therapy present difficulties for
healthcare providers. Not only must the number of
prescribed doses be correctly administered (i.e., com-
pliance), but therapy must be continued over time
(persistence). Pharmacoeconomic analyses, regard-
less of how skillfully they are applied, are of little
value if therapy cannot be adequately provided and
accepted. As a result, the solution to problems of
compliance and persistence is a control issue.
Several reports have demonstrated the problems
of maintaining patients on their lipid therapy. Over
the course of 12 months, up to 50% of patients dis-
continue their use of a prescription [1]. The mean
reduction in total cholesterol in the Lipids Research
Clinics Coronary Primary Prevention Trial (LRC-
CPPT) was approximately 10%, but the reduction
was related directly to the patient's compliance
with their prescription [2]. Those who were more
compliant had a greater reduction of low density
lipoprotein cholesterol (LDL-C) levels, and the lower
LDL-C levels were related to fewer coronary heart
disease (CHD) events [2]. The Coronary Drug Pro-
ject [3], in its evaluation of clofibrate patients, found
that those who were less adherent had 25% mor-
tality compared to 15% mortality in very adherent
patients. This relationship also held in placebo-
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groups should refer lipid patients to a central team of
professionals specializing in lipid therapy; or groups of
physicians should contract extra patient support out to
other groups, such as pharmacies. The implementation
of a compliance program will not be immediately cost-
effective but will have the long-term benefit of reduced
costs through improved health.
treated patients. The West of Scotland Coronary
Prevention Study (WOSCOPS) found that clinical
trial patients maintaining 75% or greater compli-
ance with pravastatin therapy had about a 50%
better reduction in cardiovascular disease risk than
other study patients [4]. Compliance, in and of it-
self, appears to indicate a wil!ingness to invest more
attention to health-gaining activities and lifestyle
modifications.
Noncompliance exerts a tremendous impact on
the healthcare system. Poor compliance and persis-
tence directly account for 10% of hospital admis-
sions, amounting to a drain of $25 billion of health
services each year. Further, 30-50% of prescrip-
tions fail to produce the desired results, leading to
increased morbidity, less productivity, increased
utilization of health service resources, and prema-
ture mortality, and they cost over $50 billion per
year. The most cost-effective therapy, then, will
still be overly costly and ineffective as long as there
are problems of compliance and persistence.
Solutions to the Problem of Noncompliance
Two observations are necessary before discussing
compliance-enhancing programs. The first observa-
tion is that, in the field of lipid drug therapy, the
specific drugs being used may make a difference in
compliance. Even in experienced lipid clinics, with
well-respected and highly skilled clinicians using
varied resources to help their patients persist on
their therapy, compliance still poses a problem.
This was conveyed by reports from the Milwaukee
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Veterans Administration [5]. Of 244 patients with
either coronary heart disease or peripheral vascular
disease, over the course of 1 year, only 48% were
able to tolerate the use of niacin. This is especially
striking, given the follow-up and extent of educa-
tion provided by the clinicians. Only 39% of pa-
tients taking gemfibrozil, and only 35% of those
using bile-acid sequestrants sustained the prescrip-
tion for a year. Because of its low cost, niacin is one
of the currently preferred lipid-modifying agents,
but with the expenditure of resources currently nec-
essary to sustain the poor level of compliance asso-
ciated with its use, further scrutiny is needed to as-
sess if this therapy is really cost-effective.
The second observation is that the reasons given
by patients for not following their therapy or for its
discontinuation are many. Patients may believe that
therapy is unnecessary if there is no immediacy to
their sickness; and there is a general misunderstand-
ing that once a prescription is completed, it does
not need to be refilled. The direct and indirect mes-
sages that physicians impart are also very impor-
tant since patients will not continue with therapy if
they sense that their physicians believe it to be un-
necessary. Complex, inconvenient, and prolonged
drug courses are difficult for patients to comply
with, and when side effects are perceived, patients
may focus on relatively minor aspects of a drug's
adverse effect profile. As well, negative information
on cholesterol is widespread on newscasts and has
a great influence on the public [1,6,7].
These reasons and others, which together under-
mine patient compliance, can be reduced to a dis-
crete number ofcommon factors. Considering those
in Table 1, it becomes apparent that there are nu-
merous sources of negative impact on compliance;
no one factor is responsible. As a result, there can-
not be one solution to the compliance problem. For
example, a person who is financially well-off, highly
educated, and understands the treatment, but is
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very busy with work, may forget to take the ther-
apy. All the education and financial support avail-
able will not prevent this person from simply for-
getting. Conversely, the person who can not afford
the treatment can be extensively taught about the
benefits of compliance, but until that person re-
ceives financial support, noncompliance is a cer-
tainty. The healthcare system must meet the pa-
tients at their points of need.
Practically any effort to improve compliance ap-
pears to work, at least for a short while and to a
certain extent. This may be because focusing on the
problem raises its importance. The rule of thirds
may apply here: about a third of patients will fol-
low the prescribed course of therapy because of the
physician's direction, a third may be compliant but
need encouragement to persist, and the final third
will not accept the treatment. At the start of a pro-
gram of therapy it is necessary to understand that
100% success is not a realistic possibility.
An example of how education, feedback, and
support can improve compliance was reported from
a randomized clinical trial in hypertensive patients
who, aside from monthly prescription refills, were
provided augmentation of patient education, blood
pressure checks, monitored feedback, and rewards
by their community pharmacist [8]. The group of
patients was 67% compliant with drug prescrip-
tion before augmentation; they were 92 % compli-
ant for the 6 months that augmentation was ap-
plied; and, when augmentation was removed, the
patients remitted to 70% compliance. This implies
that while compliance can be improved, it will likely
deteriorate once the intervention is removed.
The solution to noncompliance is twofold. A
compliance-enhancing program needs to be devel-
oped around the patient's needs, and an improved
system of healthcare delivery needs to be imple-
mented within the existing healthcare system.
Table I Selected causes of problems with compliance
and persistence
Treatment-based
• Complexity
• Duration
• Expense
• Side effects
• Poor directions
Attitudes
• Not sick
• Not enough value
• Fear of addiction/dependence
• Fear of developing immunity
to drug
Patient-based
• Forgetfulness
• Apathy
• Denial
• Little knowledge
• Fear
• Other priorities
• Relationship with physician
• Lack of family support
• Lack of resources
• time
• money
• transportation
Developing a Program to
Enhance Compliance
To design a compliance-enhancing program that
addresses each of the concerns previously men-
tioned, four basic elements are required: enabling,
reinforcing, prompting, and problem solving.
As the name implies, enabling prepares patients
to successfully take their medication. A key part of
enabling is good counseling. This involves effec-
tive patient education, which is not just the trans-
feral of facts or information, but the development
of a caring relationship with the patient and a true
understanding by the patient of how the medica-
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tion is to be taken. The health provider should be
approachable for questions and concerns, and the
focus should be on the patients and their needs.
Family members or friends can be involved to pro-
vide reinforcement in the home, and messages can
be reinforced with visual aids and take-home in-
formation. Sensitivity, compassion, and empathy
should be central during private counseling, and
attitudes of confrontation and lecturing should be
avoided. The enabling process, however, is more
than just good counseling. Resolving issues of ac-
cess to care and addressing cost are necessary for
the program to be effective. Patients must be as-
sured access to healthcare and to drug prescrip-
tions they can afford.
Reinforcing is simply giving the patients feed-
back on how well they are doing. This may be
achieved by providing simple praise or other re-
wards for successfully following therapy, or by
setting clear and simple goals that the patient can
follow at home, that include self-appraisal and self-
monitoring, and that involve family support.
Prompting is an effort to remind patients of
medication doses; this can involve simplifying the
drug regimen, or reminding the patients of doses
through cues, organizer systems, or stopwatches.
Finally, for the patients who in spite of the ef-
forts involved in enabling, reinforcing, and prompt-
ing, are still noncompliant, it becomes necessary to
identify specific problems and propose solutions.
This may include teaching patients problem-solving
techniques and should involve monitoring the drug
use and the outcome after a solution has been pro-
posed and introduced. The healthcare program must
identify ways to specifically target the strategies that
improve patient compliance.
Developing a Healthcare Delivery System
Once the issues affecting compliance have been ad-
dressed and a program developed, a fundamental
consideration of how to deliver the program must
be undertaken. All the compliance-improving strat-
egies listed above will be of little value if they are
not integrated into the ongoing system of health-
care delivery. It is necessary also to develop a deliv-
ery system that is cost-effective. This will involve
extra cost and extra ascribed responsibility. Al-
though pharmacists and physicians are profession-
ally obliged to counsel patients, not enough inter-
vention is currently in place to change compliance
behavior. There is also no financial incentive for
care providers to work on compliance issues. It has
been estimated that an investment of $200 per pa-
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tient per year over 5 years would increase the cost
of a year-of-life-saved by about $3000 (J. Hay, per-
sonal communication). This modest expenditure
could generate substantially improved outcomes.
The cost of implementing a program will not be neg-
ligible, but it is now time to begin thinking about
how to effectively use our resources, and how to cre-
ate incentive. Money is not currently used effectively
as an incentive; but other approaches may also
work. For example, in a capitated system, care pro-
viders may be more motivated to address noncom-
pliance if risk sharing is involved. Another incentive
may be to strengthen the Health Plan Employer
Data and Information Set (HEDIS) criteria for
lipids to include the number of patients at their
National Cholesterol Education Program (NCEP)
LDL-C goal 1 year after a myocardial infarction.
Physician groups who are interested in retaining
third party business may develop critical pathways
or other approaches to deal with compliance issues.
Organizational Models
The compliance issue in lipid therapy undoubtedly
needs the efforts of a variety of health professionals.
Although the physician has a central role, dietitians
and pharmacists are key to the success of a compli-
ance program, as are nurses, who among all profes-
sionals are perhaps the best-trained in behavioral
and social communication. The current system is in-
effective in providing compliance interventions. Pro-
fessionals deal with their own patients and there is
no real communication or coordination of responsi-
bility for different areas of compliance intervention
between all of the professionals involved. Two mod-
els of healthcare delivery are suggested.
The first model involves developing a central
lipid service in the institution of medical practice to
handle the lipid therapy of patients. One or two
physicians in a large group become the authorities
on lipid therapy and gather around them other pro-
fessionals including dieticians, pharmacists, and
nurses to help carry out the treatment courses. This
practice requires a referral system and is useful espe-
cially in large groups or centers. Support for this
model was provided by a study that compared usual
care to a central team approach [9]. Table 2 shows
that centralized team care provided more effective
treatment, but also was more expensive on a per-
patient basis. The overall cost, however, when fo-
cusing on the reduction of LDL-C, was favorable
for the team care approach.
The second model is one in which specific health-
care provider groups contract other groups to im-
prove patient support and to provide additional ed-
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Table 2 Effectiveness of a specialized lipid service*
*Adapted from [5].
tComprising a dietitian, nurse, clinical pharmacist, and medical doctor consultant.
*Reduction to 38 mgldl.
LDL-C, low density lipoprotein cholesterol.
Conclusions
Organized groups of healthcare professionals should
either route lipid therapy patients to a central spe-
cialized team or, on a center-by-center basis, con-
tract out extra patient support to other groups. The
program must meet patients at their specific levels
of need and must better utilize our resources. Efforts
to optimize delivery of health services and to imple-
ucation, monitoring, and feedback. For example,
physician groups may contract with pharmacists to
reinforce counseling and follow patient progress to-
ward treatment goals between office visits. We have
utilized community pharmacists in Virginia to pro-
vide local cholesterol testing, education, monitoring,
and feedback in one group of patients and the tradi-
tional dispensing services in another. We found that
patients without support showed 15% less compli-
ance and a 10 mg/dL increase in total cholesterol,
while patients with the extra pharmacy care showed
a 6% increase in compliance and a reduction of
11 mg/dL of total cholesterol (unpublished data).
The American Pharmaceutical Association's Project
IMPACT will soon provide a larger base of infor-
mation on this type of model. Thirty pharmacies
throughout the country were involved, linked with
physician groups, and early reports are that over
90% of patients persisted with their prescribed drug
treatment for over a year.
This article was prepared with the assistance of BioMed-
Com Consultants inc., Montreal, Canada.
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